Abstract
BackgroundPD-1/PD-L1 inhibition immunotherapy holds great promise in cancer treatment. Combination treatment using anti-PD-1/PD-L1 agents with other immunotherapeutics brings additional benefits, such as preventing refractory effects towards PD-1/PD-L1 antibodies, and improving...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have